ASH 2020 | Onvansertib plus decitabine for patients with R/R AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY discusses the results of a Phase Ib/II trial (NCT03303339) of combination therapy with onvansertib and decitabine in relapsed/refractory AML. Onvansertib inhibits PLK1, a master regulator of the cell cycle, overexpressed in AML blasts. 23 patients were treated in Phase Ib, demonstrating its tolerability, and establishing the maximum tolerated dose as 60mg/m2. A further 25 patients were recruited for Phase II. Tumor mutational profiling and ctDNA monitoring was also carried out to explore correlations with clinical responses. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Eunice Wang, MD, has participated in advisory boards for AbbVie, Astellas, BMS/Celgene, Genentech, Jazz, Kite Pharmaceuticals, Macrogenics, Novartis, Pfizer, PTC Therapeutics, Stemline and Takeda; has fulfilled speaker roles for Stemline, Pfizer and Dava Oncology; and has been a member of data monitoring committees for AbbVie and Rafael Pharmaceuticals.
